15
Participants
Start Date
October 1, 2022
Primary Completion Date
November 24, 2023
Study Completion Date
November 24, 2023
Ketohexokinase inhibition
participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
Placebo
participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
Maastricht University Medical centre, Maastricht
Collaborators (1)
Pfizer
INDUSTRY
Maastricht University Medical Center
OTHER